Trial Results Expected in the Fourth Quarter of This Year

boston_therapeutics_logo_200x100Boston Therapeutics, Inc. (OTCQB: BTHE), a developer of complex carbohydrate therapeutics to treat diabetes, has completed enrollment of its Phase IIb clinical study on BTI-320 in the United States. The study, SD-002, is being conducted by Accumed Research Associates in Garden City, NY.

The U.S. trial enrolled patients with Type 2 diabetes who are currently … Read more

logo-prima-biomed-printPrima BioMed Ltd (ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) (“Prima”, the “Company”) today announced that the abstract entitled, “Trial evaluating overall survival in epithelial ovarian cancer (EOC) patients in second remission with an autologous dendritic cell therapy targeting mucin 1″ has been accepted for a poster presentation at the Society for Immunotherapy of Cancer (“SITC”) 29th Annual Meeting.

The poster will be presented by Prima’s … Read more

logo_celatorPhase 2 Study is Designed to Support Potential New Drug Application (NDA) Submission

Celator Pharmaceuticals, Inc. (CPXX), a pharmaceutical company developing new and more effective therapies to treat cancer, today announced that the first patient has been enrolled in a Phase 2 pharmacokinetic and pharmacodynamics (PK/PD) study evaluating the effects of CPX-351 (cytarabine:daunorubicin) Liposome Injection on cardiac repolarization in adult patients with acute … Read more

anavex_logo_200x100Anavex Life Sciences Corp. (“Anavex” or the “Company”) (AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer’s disease, other diseases of the central nervous system (CNS) and various types of cancer, announced today new data published in the current issue of Cell Death and Disease that the commonly used selective serotonin reuptake inhibitor (SSRI) Fluvoxamine has a high affinity for … Read more

_get_company_logoWaferGen Bio-systems, Inc. (OTCQB: WGBS) today announced that the Company has appointed two seasoned executives to its senior management team, Keith Warner as Chief Operating Officer and Michael Henighan as Chief Financial Officer.

“We are very excited about Keith and Mike joining WaferGen. Their experience and proven track records will be great additions to the Company, and they significantly increase the depth and breadth of … Read more

boston_therapeutics_logo_200x100Boston Therapeutics, Inc. (OTCQB: BTHE), a developer of complex carbohydrate therapeutics to treat diabetes, has appointed noted diabetes specialist Jaime A. Davidson, M.D. to its Medical Advisory Board.

Dr. Davidson is clinical professor of internal medicine in the Division of Endocrinology, Touchstone Diabetes Center at The University of Texas Southwestern Medical Center in Dallas. He serves as president of WorldWIDE, a non-profit diabetes education foundation, … Read more

NXTID_Star_logoVinny Paz Follows Celebrity Shoot with Joey Fatone

NXT-ID, Inc., (NXTD) a biometric authentication company focused on the growing m-commerce market releases the second photos for the “Wocket in Your Pocket” celebrity ad campaign, featuring former boxer and world champion in the lightweight and light middleweight weight classes, Vinny Pazienza (PAZ) .


The photos were taken August 14th in Rhode Island. ( more

NXTID_Star_logoReminder Contest Closes August 17th


 NXT-ID, Inc., (NXTD) a biometric authentication company focused on the growing m-commerce market, releases new images from its current social media competition “Show us your Wallet”, #Needawocket.   

The social media contest for its next generation smart wallet, Wocket™, reveals a cross section of aging wallets as they prepare to retire and be replaced by digital wallets. Photos … Read more




CBD Energy Limited (CBDE), a diversified clean energy company and leading global provider of solar systems, has entered into an agreement with Environmental Engineering Group Thailand (EEG) to acquire 30 percent of the company.

As part of the transaction CBD intends to grant EEG a sub-license to utilize the Westinghouse Solar brand in Thailand. The company has developed a unique market … Read more

Capricor-web-Logo-medReports Encouraging Results From Phase I of the ALLSTAR Clinical Trial and Signed Exclusive License With Cedars-Sinai Medical Center for Exosomes IP Portfolio


Conference Call Scheduled for Wednesday August 13, 2014 (4:30 p.m. Eastern Time)

Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics to prevent and treat diseases, with a primary focus on heart disease, today provided a … Read more